NCT07403370 2026-02-11
Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis
Shandong Cancer Hospital and Institute
Recruiting
Clinical Trials
11 trialsNCT03118986 2025-10-08
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
The Hospital for Sick Children
Phase 2 Recruiting
NCT07035821 2025-06-25
Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy
Shanghai Children's Medical Center
Phase 3 Not yet recruiting
NCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02939287 2024-10-22
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
Phase 3 Completed
NCT05244577 2023-02-06
Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer
Sun Yat-sen University
Phase 3 Unknown
NCT03631004 2022-01-13
Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients
Instituto do Cancer do Estado de São Paulo
Phase 2/3 Completed
NCT03137121 2021-08-17
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
University of Alabama at Birmingham
Phase 2/3 Completed
NCT03571126 2021-07-13
Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
Zunyi Medical College
Phase 4 Unknown
NCT03679182 2018-09-20
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
Khon Kaen University
Phase 2 Unknown
NCT02290470 2014-11-14
Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown